Long-Term OS and Predictors in Anti–PD-1–Naive Patients With Melanoma and Brain Metastases Treated With ICIs
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study
J. Immunother. 2021 Oct 01;44(8)307-318, GS Naik, EI Buchbinder, JV Cohen, MP Manos, AEW Johnson, P Bowling, AA Aizer, JD Schoenfeld, DP Lawrence, R Haq, FS Hodi, RJ Sullivan, PA OttFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.